Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines

Our previous preclinical studies and a Phase I clinical trial DP6-001 have indicated that a polyvalent Env formulation was able to elicit broadly reactive antibody responses including low titer neutralizing antibody responses against viral isolates of subtypes A, B, C and AE. In the current report,...

Description complète

Détails bibliographiques

Auteurs principaux:	Shixia Wang, Te-hui Chou, Anthony Hackett, Veronica Efros, Yan Wang, Dong Han, Aaron Wallace, Yuxin Chen, Guangnan Hu, Shuying Liu, Paul Clapham, James Arthos, David Montefiori, Shan Lu
Format:	Artigo
Langue:	Inglês
Publié:	Taylor & Francis Group 2017-12-01
Collection:	Human Vaccines & Immunotherapeutics
Sujets:	antibody dna vaccine envelope glycoprotein heterologous prime – boost hiv-1 polyvalent protein vaccine vaccine
Accès en ligne:	http://dx.doi.org/10.1080/21645515.2017.1380137
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!